Home›Trial›NCT05049798
NCT05049798ACTIVE NOT RECRUITING

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

Study Summary

The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).

Conditions
Arthritis, Psoriatic
Interventions / Drugs
GuselkumabIL-17i
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C51/100
Study Details
Enrollment1314 participants
Primary Completion—
Lead SponsorJanssen Pharmaceutica N.V., Belgium
Data Retrieved2026-04-11 02:55:31.550736+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 1,314 participants
Sponsor Catalyst Profile

Johnson & Johnson (JNJ) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

JNJ Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.